VIVUS PT Lowered to $18.00 (VVUS)
JPMorgan Chase & Co. lowered their price objective on shares of VIVUS (NASDAQ:VVUS) from $22.00 to $18.00 in a research note issued on Wednesday, American Banking & Market News reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 85.97% from the company’s current price.
A number of other firms have also recently commented on VVUS. Analysts at Piper Jaffray Cos. downgraded shares of VIVUS from an “overweight” rating to a “neutral” rating in a research note to investors on Wednesday. They now have a $11.00 price target on the stock, down previously from $14.00. Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of VIVUS in a research note to investors on Friday, October 11th. They now have a $20.00 price target on the stock. Finally, analysts at Leerink Swann reiterated an “outperform” rating on shares of VIVUS in a research note to investors on Thursday, October 3rd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $14.45.
Shares of VIVUS (NASDAQ:VVUS) traded down 3.79% on Wednesday, hitting $9.679. 4,022,630 shares of the company’s stock traded hands. VIVUS has a 52-week low of $9.11 and a 52-week high of $22.72. The stock’s 50-day moving average is $10.63 and its 200-day moving average is $12.51. The company’s market cap is $976.2 million. VIVUS also was the target of some unusual options trading on Monday. Stock investors purchased 7,795 put options on the stock. This is an increase of approximately 322% compared to the average daily volume of 1,846 put options.
VIVUS (NASDAQ:VVUS) last announced its earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.11. The company had revenue of $5.53 million for the quarter, compared to the consensus estimate of $12.76 million. During the same quarter last year, the company posted ($0.24) earnings per share. On average, analysts predict that VIVUS will post $-1.99 earnings per share for the current fiscal year.
VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.